6 results
Search Results
2. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
- Author
-
DeWilde, Kaitlin E., Levitch, Cara F., Murrough, James W., Mathew, Sanjay J., and Iosifescu, Dan V.
- Subjects
THERAPEUTICS ,MENTAL depression ,KETAMINE ,TREATMENT effectiveness ,ANTIDEPRESSANTS ,METHYL aspartate receptors ,PUBLIC health ,CLINICAL trials - Abstract
Major depressive disorder (MDD) is one of the most disabling diseases worldwide and is becoming a significant public health threat. Current treatments forMDDprimarily consist of monoamine-targeting agents and have limited efficacy. However, the glutamate neurotransmitter system has recently come into focus as a promising alternative for novel antidepressant treatments. We review the current data on the glutamate NMDA receptor antagonist ketamine, which has been shown in clinical trials to act as a rapid antidepressant inMDD.We also examine ketamine efficacy on dimensions of psychopathology, including anhedonia, cognition, and suicidality, consistent with theNIMH Research Domain Criteria initiative. Other aspects of ketamine reviewed in this paper include safety and efficacy, different administration methods, and the risks of misuse of ketamine outside of medical settings. Finally, we conclude with a discussion of glutamatergic agents other than ketamine currently being tested as novel antidepressants. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Treatment in Lambert-Eaton myasthenic syndrome.
- Author
-
Maddison, Paul
- Subjects
LAMBERT-Eaton myasthenic syndrome ,ANTINEOPLASTIC agents ,PARANEOPLASTIC syndromes ,QUANTITATIVE research ,CLINICAL trials ,MYASTHENIA gravis ,STEROIDS ,META-analysis ,THERAPEUTICS - Abstract
Besides antitumor therapy for patients with the paraneoplastic form of Lambert-Eaton myasthenic syndrome (LEMS), the mainstay of symptomatic treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). Data from four randomized, placebo-controlled trials have revealed that muscle strength scores increased significantly with 3,4-DAP. A limited meta-analysis performed on two trials using the Quantitative Myasthenia Gravis score indicated that the clinical benefits seen were modest. Meta-analysis of the mean change in compound muscle action potential amplitude following 3,4-DAP treatment revealed a significant improvement compared to placebo. However, most patients with noncancer LEMS require long-term immunosuppression, usually with prednisolone and azathioprine. A single crossover study has previously shown significant short-term benefit in limb strength following intravenous immunoglobulin, and there are isolated case reports of medium term benefit from rituximab. Overall, a combination of symptomatic treatment with 3,4-DAP and immunosuppression, with or without antitumor therapy, is often successful for most LEMS patients, with other more aggressive regimens rarely needed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Potential pathophysiological mechanisms in osteonecrosis of the jaw.
- Author
-
Landesberg, Regina, Woo, Victoria, Cremers, Serge, Cozin, Matthew, Marolt, Darja, Vunjak‐Novakovic, Gordana, Kousteni, Stavroula, and Raghavan, Srikala
- Subjects
PATHOLOGICAL physiology ,OSTEONECROSIS ,JAW diseases ,BONE metastasis ,BONE mechanics ,DIPHOSPHONATES ,CLINICAL trials ,THERAPEUTICS - Abstract
Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications associated with metastastic bone disease, Paget's disease, and osteoporosis. Osteonecrosis of the jaw (ONJ) is a recently described clinical condition that has been associated with the use of nitrogen-containing bisphosphonates. Reports describing this entity first appeared in the literature in 2003. While there have been significant numbers of case reports and a limited number of retrospective and prospective studies examining risk factors associated with ONJ, the pathophysiology of this condition remains elusive. In this review, we explore proposed mechanisms underlying ONJ development and identify potential areas for future investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis.
- Author
-
Sanders, Donald B. and Siddiqi, Zaeem A.
- Subjects
CLINICAL trials ,MYASTHENIA gravis treatment ,RESEARCH methodology evaluation ,PREDNISONE ,NEUROMUSCULAR diseases ,MEDICAL experimentation on humans ,THERAPEUTICS ,EVALUATION - Abstract
Two randomized controlled trials of mycophenolate mofetil (MMF) in the treatment of myasthenia gravis (MG) were recently completed. Although neither study demonstrated efficacy of MMF in the population of patients studied, there are valuable lessons in the way these studies were developed and performed. After reviewing the design and results of these trials, we discuss possible reasons leading to negative results and the lessons learned, which should be useful for future clinical trials in MG. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Opportunities for New Therapies Based on the Natural Regulators of Complement Activation.
- Author
-
BROOK, EVE, HERBERT, ANDREW P., JENKINS, HUW T., SOARES, DINESH C., and BARLOW, PAUL N.
- Subjects
THERAPEUTICS ,MEDICAL research ,IMMUNITY ,CLINICAL trials ,ENZYME activation - Abstract
While the complement system is an essential component of immunity, shutting down all or part of it could be beneficial in a wide range of clinical situations. Designer, small-molecule, protease inhibitors and antagonists of protein-protein interactions are under development, while an approach based on a humanized monoclonal antibody to the C5 component works effectively against the later stages of complement activation and is close to completing clinical trials. The cobra venom factor depletes plasma of essential complement components, and a humanized (nonimmunogenic) version is being sought. Perhaps the most promising approach to comprehensive complement downregulation, however, is the exploitation of innate regulators of complement activation, with two products in clinical trials. The potential for more efficacious complement blockers of this kind is growing because of better targeting, but a deeper knowledge at the atomic level of mechanisms of action of these regulators is needed to underpin a rational approach to design of still more potent complement inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.